| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. The AWMSG Scrutiny Panel considered trientine dihydrochloride (Cufence®) suitable for a full assessment at their meeting on 04/06/2026. Any resulting AWMSG advice will also apply to other formulations of trientine, such as Cuprior® with similar or lower cost. |
|
Medicine details |
|
| Medicine name | trientine tetrahydrochloride (Cuprior®) |
| Formulation | 150 mg tablet |
| Reference number | 3622 |
| Indication | Treatment of Wilson’s disease in adults, adolescents and children ≥ 5 years intolerant to D-penicillamine therapy |
| Company | GMP-Orphan SA |
| BNF chapter | Nutrition & blood |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 16/03/2020 |